Skip to main content

Animations

MJFF Publications

5151 - 5160 of 8673 Results
Title
Year
  • Year
  • 2018
  • 2025
  • 2023
  • 2025
  • 2018
  • 2019
  • 2023
  • 2019
  • 2025
  • 2022
  • Summary Details
    OPEN
    Title: Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy
    Journal Name: Molecular Neurodegeneration
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s13024-018-0245-9
    Citation Count: 65
  • Summary Details
    OPEN
    Title: Human pegivirus alters brain and blood immune and transcriptomic profiles of patients with Parkinson’s disease
    Journal Name: JCI Insight
    Publisher: American Society for Clinical Investigation
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1172/jci.insight.189988
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Neuroprotective actions of a fatty acid nitroalkene in Parkinson’s disease
    Journal Name: npj Parkinson's Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41531-023-00502-3
    Citation Count: 8
  • Summary Details
    OPEN
    Title: Regulation of LRRK2 activity by metabolic stress and heavy metal exposure
    Journal Name: Brain Research
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.brainres.2025.149785
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: publisher-specific-oa
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2018.10.005
    Citation Count: 17
  • Summary Details
    OPEN
    Title: PINK1 phosphorylates ubiquitin predominantly in astrocytes
    Journal Name: npj Parkinson's Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41531-019-0101-9
    Citation Count: 40
  • Summary Details
    OPEN
    Title: A Fixable Fluorescence‐Quenched Substrate for Quantitation of Lysosomal Glucocerebrosidase Activity in Both Live and Fixed Cells
    Journal Name: Angewandte Chemie
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/ange.202309306
    Citation Count: 0
  • Summary Details
    OPEN
    Title: A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson’s disease
    Journal Name: Science Translational Medicine
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1126/scitranslmed.aau6870
    Citation Count: 94
  • Summary Details
    OPEN
    Title: Alpha-synuclein is increased in erythrocytes in parkinson’s disease cases
    Journal Name: Scientific Reports
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1038/s41598-025-11979-8
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels
    Journal Name: Acta Neuropathologica Communications
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s40478-021-01307-2
    Citation Count: 51
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.